Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether

Drug Metabolism and Disposition

Volumn 36, Issue 11, 2008, Pages 2234-2243

  Sridar, Chitra ^a   Kent, Ute M ^a   Noon, Kate ^a   McCall, Alecia ^c   Alworth, Bill ^b   Foroozesh, Maryam ^c   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Tulane University   (United States)

^c XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 (4 TRIFLUOROMETHYL) COUMARIN PROPARGYL ETHER; 7 COUMARIN PROPARGYL ETHER; COUMARIN DERIVATIVE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEBENZYLATION; DRUG METABOLISM; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SPECTROSCOPY;

ALKYNES; COUMARINS; CYTOCHROME P-450 CYP3A; ENZYME ACTIVATION; ENZYME INHIBITORS; ETHERS; HUMANS; IMIDAZOLES; MICROSOMES, LIVER;

EID: 54349127112     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021493     Document Type: Article

References (37)

1. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, and Gelboin HV (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264:10388-10395.
2. Baer BR, Wienkers LC, and Rock DA (2007) Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol 20:954-964.
3. Bargetzi MJ, Aoyama T, Gonzalez FJ, and Meyer UA (1989) Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 46:521-527.
4. Blobaum AL, Kent UM, Alworth WL, and Hollenberg PF (2002) Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein. Chem Res Toxicol 15:1561-1571.
5. Born SL, Fix AS, Caudill D, and Lehman-McKeeman LD (1998) Selective Clara cell injury in mouse lung following acute administration of coumarin. Toxicol Appl Pharmacol 151:45-56.
6. Buters JT, Schiller CD, and Chou RC (1993) A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man: direct fluorescence monitoring of the deethylation of 7-ethoxy-4- trifluoromethylcoumarin. Biochem Pharmacol 46:1577-1584.
7. Cho US, Park EY, Dong MS, Park BS, Kim K, and Kim KH (2003) Tight-binding inhibition by α-naphthoflavone of human cytochrome P450 1A2. Biochim Biophys Acta 1648:195-202.
8. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, and Hall SD (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317-1327.
9. Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
10. i values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
11. Gillam EM, Baba T, Kim BR, Ohmori S, and Guengerich FP (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 305:123-131.
12. Gillam EM, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PE, Hooper WD, and Guengerich FP (1995) Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 317:374-384.
13. Gorski JC, Hall SD, Jones DR, VandenBranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
14. Hanna IH, Teiber JF, Kokones KL, and Hollenberg PF (1998) Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch Biochem Biophys 350:324-332.
15. Kamdem LK, Streit F, Zanger UM, Brockmöller J, Oellerich M, Armstrong VW, and Wojnowski L (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374-1381.
16. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
17. Khan KK, He YQ, Correia MA, and Halpert JR (2002) Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos 30:985-990.
18. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
19. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
20. Lake BG (1999) Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem Toxicol 37:423-453.
21. Lewis DF, Ito Y, and Lake BG (2006) Metabolism of coumarin by human P450s: a molecular modelling study. Toxicol In Vitro 20:256-264.
22. Lin HL, Kent UM, and Hollenberg PF (2002) Mechanism-based inactivation of cytochrome P345 3A4 by 17-alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J Pharmacol Exp Ther 301:160-167.
23. Marshall ME, Butler K, Cantrell J, Wiseman C, and Mendelsohn L (1989) Treatment of advanced malignant melanoma with coumarin and cimetidine: a pilot study. Cancer Chemother Pharmacol 24:65-66.
24. Ortiz de Montellano PR and Kunze KL (1980) Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates. J Biol Chem 255:5578-5585.
25. Roberts ES, Hopkins NE, Foroozesh M, Alworth WL, Halpert JR, and Hollenberg PF (1997) Inactivation of cytochrome P450s 2B1, 2B4, 2B6, and 2B11 by arylalkynes. Drug Metab Dispos 25:1242-1248.
26. 3H-labeled 2-ethynylnaphthalene-inactivated P450 2B1 and 2B4 using amino acid sequencing and mass spectrometry. Biochemistry 33:3766-3771.
27. Shimada T, Yamazaki H, Foroozesh M, Hopkins NE, Alworth WL, and Guengerich FP (1998) Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol 11:1048-1056.
28. Soine TO (1964) Naturally occurring coumarins and related physiological activities. J Pharm Sci 53:231-264.
29. Strobel SM, Szklarz GD, He Y, Foroozesh M, Alworth WL, Roberts ES, Hollenberg PF, and Halpert JR (1999) Identification of selective mechanism-based inactivators of cytochromes P-450 2B4 and 2B5, and determination of the molecular basis for differential susceptibility. J Pharmacol Exp Ther 290:445-451.
30. Teiber JF and Hollenberg PF (2000) Identification of the human liver microsomal cytochrome P450s involved in the metabolism of N-nitrosodi- n-propylamine. Carcinogenesis 21:1559-1566.
31. Von Weymarn LB, Sridar C, and Hollenberg PF (2004) Identification of amino acid residues involved in the inactivation of cytochrome P450 2B1 by two acetylenic compounds: the role of three residues in nonsubstrate recognition Sites. J Pharmacol Exp Ther 311:71-79.
32. Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, and Martin E (1994) Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J. Anaesth 73:658-661.
33. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AY (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366.
34. Wang YH, Jones DR, and Hall SD (2005) Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 33:664-671.
35. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, and VandenBranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207-213.
36. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, and Watkins PB (2000) The human CYP3A subfamily: practical considerations. Drug Metab Rev 32:339-361.
37. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.